PharmaShots | Incisive News in 3 Shots

Subscribe Now

Merck

Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

Merck Reports the Data from P-III Study Assessing Subcutaneous Keytruda with Berahyaluronidase Alfa to Treat Metastatic NSCLC

November 20, 2024

Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)

Merck Reports the CHMP’s Positive Opinion of Keytruda Plus CT as a 1L Treatment of Unresectable Non-Epithelioid Malignant Pleural...

November 18, 2024

Merck Join Forces with LaNova Medicines to Advance LM-299 for Advanced Solid Tumors

Merck Join Forces with LaNova Medicines to Advance LM-299 for Advanced Solid Tumors

November 15, 2024

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers

October 24, 2024

Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024

Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWee...

October 21, 2024

Merck Highlights the P-IIb/III (MK-1654-004) Study Data of Clesrovimab to Prevent RSV Disease in Healthy Preterm and Full-term Infantsat IDWeek 2024

Merck Highlights the P-IIb/III (MK-1654-004) Study Data of Clesrovimab to Prevent RSV Disease in Healthy Preterm and Full-term Inf...

October 18, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us